Clinical trials: Colonic Cancer
Colorectal Polyp, Colorectal Neoplasms
Real-time AI-assisted Endocyroscopy for the Diagnosis of Colorectal Lesions
Colorectal cancer (CRC) is the third most common malignancy and the second leading cause of cancer-related death worldwide. Colonoscopy is considered the preferred method of screening for colorectal cancer, and early and…
- Trial name
- NCT06791395
- Testing
- Computer-aided diagnosis (CADx) support tool
- Where
- 3 sites in China
- Volunteers
- 570 people
- Sponsor
- The First Hospital of Jilin University
Locally Advanced Solid Tumors, Metastatic Solid Tumors
A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
Phase 1 dose escalation will determine the first cycle dose-limiting toxicities (DLTs), the maximum tolerated dose (MTD), the biologically effective dose and recommended Phase 2 dose (RP2D) of repotrectinib given to adult…
- Trial name
- TRIDENT-1 (NCT03093116)
- Testing
- Oral repotrectinib (TPX-0005)
- Where
- 165 sites in United States, Australia and 17 more
- Volunteers
- 500 people
- Sponsor
- Turning Point Therapeutics, Inc.
Colorectal Cancer
Tissue and Serum Collection From Colorectal Cancer Patients
To establish a serum and tissue bank with specimens form patients with colorectal cancer, for subsequent immunological and biochemical analysis.
- Trial name
- NCT00579891
- Where
- United States
- Volunteers
- 726 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Advanced Solid Tumor
A Phase I/IIa Study of JAB-23E73 in Patients With Advanced Solid Tumors Harboring KRAS Gene Alteration
This is a multicenter, open-label, phase I/IIa to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of pan-KRAS inhibitor JAB-23E73 in patients with advanced solid…
- Trial name
- NCT06959615
- Testing
- JAB-23E73
- Where
- 32 sites in China
- Volunteers
- 334 people
- Sponsor
- Jacobio Pharmaceuticals Co., Ltd.
Colorectal Neoplasm
Recombinant Human Endostatin in Combination With mFOLFOX6 in Patients With Metastatic Colorectal Cancer
To investigate safety and tolerance of dose-escalation of infusional recombinant human endostatin in combination with mFOLFOX6 as initial therapy for patients with metastatic colorectal cancer.
- Trial name
- NCT01310478
- Testing
- recombinant human endostatin (Endostat)
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Fudan University
Irritable Bowel Syndrome, Colitis, Ulcerative
Advanced Metagenomic Analysis of Human Colonic Microbiota in Patients With Chronic GI Disorders
This clinical trial hypothesize that Gut Microbiota (bacteria, viruses, fungi)play a major role in the occurrence and progression of many chronic gastrointestinal diseases like Irritable Bowel Syndrome, Inflammatory Bowel…
- Conditions
- Irritable Bowel Syndrome, Colitis, Ulcerative, Crohn Disease, Colonic Neoplasms
- Trial name
- NCT01099111
- Where
- Saudi Arabia
- Volunteers
- 225 people, healthy volunteers welcome
- Sponsor
- King Fahad Medical City
Colorectal Cancer
The Feasibility of an Active Lifestyle Programme in Patients Recovering From Colorectal Cancer
Long-term maintenance of physical activity behaviour change post-intervention remains challenging. This study is investigating the feasibility of a behaviour change intervention based on Self-Determination Theory in people…
- Trial name
- MOVE (NCT02751892)
- Testing
- Active lifestyle programme
- Volunteers
- 28 people
- Sponsor
- University of East Anglia
Metastatic Colorectal Cancer
HepaSphere™ Microspheres Prospective Registry
HepaSphere™ Microspheres loaded with irinotecan received CE mark for the indication of use in embolization of metastatic colorectal cancer (mCRC) to the liver in 2015.
- Trial name
- mCRC (NCT04866290)
- Testing
- HepaSphere Microspheres
- Where
- 2 sites in France, Greece
- Volunteers
- 105 people
- Sponsor
- Merit Medical Systems, Inc.
Colorectal Cancer (CRC), Pancreatic Cancer
Expanded Access Program (EAP) Designed to Provide Access to Botensilimab and Balstilimab Before Regulatory Approval
This is an expanded access program (EAP) designed to provide access to Botensilimab and Balstilimab prior to drug registration by the applicable local regulatory agency.
- Conditions
- Colorectal Cancer (CRC), Pancreatic Cancer, Non-Small Cell Lung Cancer (NSCLC), Hepatocellular Carcinoma (HCC)
- Trial name
- NCT06751524
- Testing
- Botensilimab, Balstililmab
- Sponsor
- Agenus Inc.
Colonic Cancer
Open Versus Laparoscopic Right Hemicolectomy for Right Colon Cancer
The aim of this study is to demonstrate the feasibility, surgical, and oncologic outcomes of laparoscopic right hemicolectomy with CME and CVL compared to open surgery.
- Trial name
- CME (NCT04434508)
- Testing
- laparoscopic right hemicolectomy with CME and central v, Open right hemicolectomy with CME and central v
- Where
- Egypt
- Volunteers
- 90 people
- Sponsor
- Mansoura University
Colon Cancer, Rectal Cancer
Exploratory Study Of The ERCC-1 Gene
This study is for patients with advanced or stage II and III colon or rectal cancer. The primary purpose of this research study is to determine if a particular protein in the patient's blood will change when they receive…
- Trial name
- NCT00846482
- Testing
- Oxaliplatin
- Where
- 2 sites in United States
- Volunteers
- 64 people
- Sponsor
- Albert Einstein College of Medicine
Colorectal Cancer, Colon Polyp
Colorectal Cancer Screening Using Stool DNA-based SDC2 Methylation Test
A study of colorectal cancer screening using stool DNA-based SDC2 methylation test
- Conditions
- Colorectal Cancer, Colon Polyp, Healthy
- Trial name
- NCT04304131
- Testing
- Earlytect Colon Cancer
- Where
- 8 sites in South Korea
- Volunteers
- 1,210 people
- Sponsor
- Kyung Hee University Hospital at Gangdong
Advanced or Recurrent Colorectal Cancer
Panitumumab for Intravenous Infusion 100 mg and 400 mg Special Drug Use Surveillance "Survey on Unresectable, Advanced or Recurrent Colorectal Cancer With Wild-type KRAS Gene" (All-patient Surveillance)
The efficacy and safety of panitumumab (Vectibix) in the routine clinical setting will be studied. Specifically, information will be collected on the following as events of interest: skin disorders, interstitial lung disease…
- Trial name
- NCT02089737
- Testing
- Panitumumab
- Volunteers
- 3,091 people
- Sponsor
- Takeda
Colorectal Cancer
Carbohydrate Antigen 19-9 in Colorectal Cancer
4,972 patients who underwent surgery for primary CRC between January 2004 and December 2015 at Seoul National University Hospital were retrospectively reviewed.
- Trial name
- NCT04999072
- Testing
- Colectomy for colon cancer
- Where
- South Korea
- Volunteers
- 4,972 people
- Sponsor
- Seoul National University Hospital
Metastatic Colorectal Cancer, Radiotherapy
Consolidative Radiotherapy Plus Maintenance Chemotherapy for Metastatic Colorectal Cancer
This study is a randomized phase II trial of maintenance chemotherapy versus consolidative radiotherapy plus maintenance chemotherapy for patients with unresectable metastatic colorectal cancer (MCRC).
- Trial name
- MCRC-LC1 (NCT03142282)
- Testing
- maintenance chemotherapy, Consolidative Radiotherapy
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Gut Microbiome, Gastrointestinal Microbiome
A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Disease
This study seeks to correlate microbiome sequencing data with information provided by patients and their medical records.
- Conditions
- Gut Microbiome, Gastrointestinal Microbiome, Autism, Autism Spectrum Disorder
- Trial name
- NCT04031469
- Testing
- There is no intervention in this study
- Where
- United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- ProgenaBiome
Colorectal Cancer, Colorectal Adenocarcinoma
The Effect of Minimally Invasive Surgery on Systemic Inflammatory Response in Rectal Cancer
As a hypothesis and shown in many meta-analyses and randomized controlled studies, minimally invasive surgery causes less surgical trauma and therefore less proinflammatory response and immunosuppression develop, and…
- Conditions
- Colorectal Cancer, Colorectal Adenocarcinoma, Rectal Cancer, Rectal Cancer Stage
- Trial name
- NCT06540027
- Testing
- rectal cacer surgery
- Where
- Turkey (Türkiye)
- Volunteers
- 80 people
- Sponsor
- Başakşehir Çam & Sakura City Hospital
Colorectal Neoplasms, RAS
The Safety and Efficacy of Cetuximab Beta Plus Fruquintinib With or Without Immune Checkpoint Inhibitorrs in First-line Treatment of RAS/BRAF Wild Type Unresectable Metastatic Colorectal Cancer
Colorectal cancer is a malignant tumor ranking among the top four in incidence and the top three in causes of death globally . Chemotherapy combined with anti-EGFR or anti-VEGF monoclonal antibodies is currently the standard…
- Conditions
- Colorectal Neoplasms, RAS, BRAF, Cetuximabβ
- Trial name
- concept (NCT07257653)
- Testing
- Cetuximab β；Fruquintinib；, Cetuximab β；Fruquintinib；anti-PD1 antibody；, Cetuximab β；Fruquintinib；anti-PD1/CTLA4 antibody
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Zhejiang University
Colorectal Neoplasms
Artificial Intelligence for Diminutive Polyp Characterization
Artificial intelligence is a promising tool that may have a role in characterizing colon epithelial lesions (CADx), helping to get a reliable optical diagnosis regardless of the endoscopist experience.
- Trial name
- NCT05391477
- Testing
- GI-Genius artificial intelligence
- Where
- Spain
- Volunteers
- 643 people
- Sponsor
- Hospital Universitario La Fe
Colorectal Cancer
RAD001, FOLFOX and Bevacizumab in Treatment of Colorectal Carcinoma
RAD001 (everolimus) is a novel oral derivative of rapamycin. RAD001 has been in clinical development since 1996 as an immunosuppressant in solid organ transplantation and has obtained marketing authorization (Certican®) for…
- Trial name
- NCT01047293
- Testing
- RAD001, FOLFOX, Bevacizumab
- Where
- 2 sites in United States
- Volunteers
- 47 people
- Sponsor
- University of Utah